The Alzheimer’s Drugs Market is predicted to reach US$ ~9.67 billion by 2031 from US$ ~4.5 billion in 2020, and to grow at a CAGR of ~7.2% between the forecast period 2021 to 2031.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2021 to 2031. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2020. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
Drug Type [NMDA Receptor Antagonists and Cholinesterase Inhibitors], Distribution Channel [Hospital Pharmacy, Retail Pharmacy and Online Pharmacy]
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Daiichi Sankyo Company, Ltd, H. Lundbeck A/S, Novartis AG, Lupin Pharmaceuticals, Inc., Actiza Pharmaceutical Private Limited, Amneal Pharmaceuticals LLC., AC Immune, F. Hoffmann-La Roche Ltd, Janssen Global Services, and LLC, AbbVie Inc., among others.
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2018 & 2019
2. Base Year - 2020
3. Forecasted Years - 2021 to 2031
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Alzheimer’s Drugs Market - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Alzheimer’s Drugs Market - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Alzheimer’s Drugs Market - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Alzheimer’s Drugs Market - ANALYSIS & FORECAST, BY REGION
North America Alzheimer’s Drugs Market
1. North America Alzheimer’s Drugs Market, by Country
1. US
2. Canada
1. North America Alzheimer’s Drugs Market, by Product
2. North America Alzheimer’s Drugs Market, by Type
3. North America Alzheimer’s Drugs Market, by Gender
4. North America Alzheimer’s Drugs Market, by Sales Channel
3. Europe Alzheimer’s Drugs Market
1. Europe Alzheimer’s Drugs Market, by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Alzheimer’s Drugs Market, by Product
3. Europe Alzheimer’s Drugs Market, by Type
4. Europe Alzheimer’s Drugs Market, by Gender
5. Europe Alzheimer’s Drugs Market, by Sales Channel
4. Asia Pacific Alzheimer’s Drugs Market
1. Asia Pacific Alzheimer’s Drugs Market, by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Alzheimer’s Drugs Market, by product
3. Asia Pacific Alzheimer’s Drugs Market, by Type
4. Asia Pacific Alzheimer’s Drugs Market, by Gender
5. Asia Pacific Alzheimer’s Drugs Market, by Sales Channel
5. Rest of the World Alzheimer’s Drugs Market
1. Rest of the World Alzheimer’s Drugs Market, by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Alzheimer’s Drugs Market, by Product
3. Rest of the World Alzheimer’s Drugs Market, by Type
4. Rest of the World Alzheimer’s Drugs Market, by Gender
5. Rest of the World Alzheimer’s Drugs Market, by Sales Channel
2. COMPANY PROFILES
Company 1, Company 5